Effect of anrukinzumab compared with placebo on clinical endpoints at Week 14
| Placebo (n=12) | Anrukinzumab 200 mg (n=15) | Anrukinzumab 400 mg (n=16) | Anrukinzumab 600 mg (n=13) | |
|---|---|---|---|---|
| Change from baseline in total Mayo score Mean (80% CI) | −1.32 (−2.33 to −0.30) | −2.28 (−3.19 to −1.37) | −2.30 (−3.18 to −1.42) | −0.79 (−1.76 to 0.19) |
| Patients with mucosal healing n (%) (80% CI) | 4 (33.3) (18.9 to 51.8) | 5 (33.3) (20.1 to 49.9) | 7 (43.8) (29.2 to 59.5) | 2 (15.4) (6.6 to 32.0) |
| Patients with improvement of rectal bleeding n (%) | 4 (33.3) | 8 (53.3) | 7 (43.8) | 5 (38.5) |
| Patients with improvement of Mayo endoscopic subscore n (%) | 6 (50.0) | 8 (53.3) | 11 (68.8) | 2 (15.4) |
| Clinical response rate n (%) | 5 (41.7) | 9 (60.0) | 8 (50.0) | 2 (15.4) |
| Clinical remission rate n (%) | 2 (16.7) | 5 (33.3) | 3 (18.8) | 0 (0) |
A total of nine, six, five and eight subjects were missing in placebo and anrukinzumab 200, 400 and 600 mg groups, respectively. Among them, nine, six, four and eight subjects were missing due to dropout; the rest were missing due to other reasons.